Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.
Mueller S, Fangusaro J, Thomas AO, Jacques TS, Bandopadhayay P, de Blank P, Packer RJ, Fouladi M, van Meeteren AS, Jones D, Perry A, Nakano Y, Hargrave D, Riedl D, Robison NJ, Partanen M, Fisher MJ, Witt O. Mueller S, et al. Among authors: fisher mj. Neuro Oncol. 2024 Mar 4;26(3):407-416. doi: 10.1093/neuonc/noad227. Neuro Oncol. 2024. PMID: 38146999
Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu GT. Fisher MJ, et al. Neuro Oncol. 2012 Jun;14(6):790-7. doi: 10.1093/neuonc/nos076. Epub 2012 Apr 3. Neuro Oncol. 2012. PMID: 22474213 Free PMC article.
Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma.
Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, D'Agostino McGowan L, Liu GT. Fisher MJ, et al. Ann Neurol. 2014 May;75(5):799-800. doi: 10.1002/ana.24157. Epub 2014 May 14. Ann Neurol. 2014. PMID: 24740685 No abstract available.
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.
Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH, Harter DH, Goldberg JD, Hochman T, Merkelson A, Bloom MC, Sievert AJ, Resnick AC, Dhall G, Jones DT, Korshunov A, Pfister SM, Eberhart CG, Zagzag D, Allen JC. Karajannis MA, et al. Among authors: fisher mj. Neuro Oncol. 2014 Oct;16(10):1408-16. doi: 10.1093/neuonc/nou059. Epub 2014 May 6. Neuro Oncol. 2014. PMID: 24803676 Free PMC article. Clinical Trial.
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, Perentesis J, Schorry E, Ullrich N, Gutmann DH, Tonsgard J, Viskochil D, Korf B, Packer RJ, Fisher MJ. Weiss B, et al. Among authors: fisher mj. Neuro Oncol. 2015 Apr;17(4):596-603. doi: 10.1093/neuonc/nou235. Epub 2014 Oct 14. Neuro Oncol. 2015. PMID: 25314964 Free PMC article. Clinical Trial.
474 results